CD33 and acute myeloid leukemia: To address the challenges of antigen escape, limited plasma half-life, and treatment-related toxicity in AML therapy, Zeng et al. designed an innovative dual-targeting T cell engager (CD33/CD123 NANOBODY TCE) using the NANOBODY platform.